Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Liabilities and Shareholders Equity (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $150.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 114.49% to $150.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $732.7 million through Dec 2025, up 98.71% year-over-year, with the annual reading at $150.8 million for FY2025, 114.49% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $150.8 million at Whitehawk Therapeutics, down from $167.0 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $234.0 million in Q1 2025, with the low at $37.4 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $137.5 million, with a median of $146.6 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity surged 245.76% in 2022, then crashed 46.9% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $157.9 million in 2021, then rose by 16.67% to $184.2 million in 2022, then dropped by 28.12% to $132.4 million in 2023, then plummeted by 46.9% to $70.3 million in 2024, then skyrocketed by 114.49% to $150.8 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $150.8 million, $167.0 million, and $180.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.